CLIMB BIO, INC. (CLYM)
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
ABM Reports Fiscal Second Quarter 2026 Results and Reaffirms Fiscal 2026 Adjusted EPS Outlook